Could cause temporary or reversible harm; serious harm is unlikely.
Subpotent Product: assay results for Amoxicillin were below the specification limits.
| Distributed by / for | Teva Pharmaceuticals USA, INC. North Wales, PA 19454 |
| NDC | 0093-4150-80 |
| Full product label | Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in (a) 150 mL bottle (NDC 0093-4150-80) (b) 80 mL bottle (NDC 0093-4150-79), Rx Only, Manufactured in Canada By: Teva Canada Limited Toronto, Canada, M1B2K9, Manufactured For: Teva Pharmaceuticals USA, INC. North Wales, PA 19454. |
| Recalling firm | Teva Pharmaceuticals USA |
| Distribution | Nationwide in the USA and Puerto Rico |
| Quantity | 171,488 150 mL and 80 mL bottles |
| Recall initiated | 2019-04-12 |
| Report date | 2019-04-24 |
| Recall completed | 2020-07-08 |
| Recall number | D-1205-2019 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | North Wales PA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗